|
| Press Releases |
|
 |
|
| Tuesday, December 1, 2020 |
|
|
BioVaxys Provides Viral Vaccine Platform Program Update |
| BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB) ("BioVaxys" or "the Company") is pleased to announce that it has received further data from its successfully completed murine model study demonstrating that immunizing mice with two doses of BVX-0320, its COVID-19 vaccine candidate, induced high levels of antibodies against the S1 fragment of the SARS-CoV-2 spike protein associated with inhibition of the binding of the virus to cells of the respiratory tract. more info >> |
|
| Monday, November 30, 2020 |
|
|
BioVaxys Provides Viral Vaccine Platform Program Update |
| BioVaxys Technology Corp. (CSE: BIOV) is pleased to announce that it has received further data from its successfully completed murine model study demonstrating that immunizing mice with two doses of BVX-0320, its COVID-19 vaccine candidate, induced high levels of antibodies against the S1 fragment of the SARS-CoV-2 spike protein associated with inhibition of the binding of the virus to cells of the respiratory tract. more info >> |
|
| Wednesday, November 11, 2020 |
|
|
BioVaxys Announces 96.4 Percent Positive Antibody Immune Response Results from an In Vivo Murine Model Study of Its SARS-CoV-2 Vaccine |
| BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB) ("BioVaxys") is pleased to announce that results from its preclinical animal study (also known as the "murine model study") of BVX-0320, its Covid-19 vaccine candidate, show that the vaccine elicits a positive immune response against the SARS-CoV-2 s-spike protein. more info >> |
|
| Monday, November 2, 2020 |
|
|
BioVaxys Files Patent Application for Novel COVID-19 Diagnostic for T-Cell Immunity |
| BioVaxys Technology Corp. (CSE: BIOV) ("BioVaxys" or "the Company"), a world leader in haptenized protein vaccine research and development, announced today that it has filed a Provisional Patent Application with the U.S. Patent and Trademark Office entitled METHOD AND KIT FOR DETECTION OF CELL MEDIATED IMMUNE RESPONSE related to the potential development of a diagnostic for evaluating the presence or absence of a T-cell immune response to SARS-CoV-2, the virus that causes COVID-19. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
Anytime Fitness Accelerates Asia-Pacific Expansion
May 12, 2026 22:56 HKT/SGT
|
|
|
Redington MD and Group CEO V.S. Hariharan Appointed to GTDC Executive Committee
May 12, 2026 21:00 HKT/SGT
|
|
|
GMG Leases New Site for Production & Office Expansion
May 12, 2026 20:29 HKT/SGT
|
|
|
CANEX and Gold Basin Resources Announce Arrangement Agreement to Facilitate CANEX'S Acquisition of Remaining Gold Basin Shares
May 12, 2026 19:30 HKT/SGT
|
|
|
GIC進一步增持歌禮製藥-B（1672.HK）超1千萬股 持股比例升至7.00% 彰顯長期發展信心
May 12, 2026 19:12 HKT/SGT
|
|
|
GIC进一步增持歌礼制药-B（1672.HK）超1千万股 持股比例升至7.00% 彰显长期发展信心
May 12, 2026 19:12 HKT/SGT
|
|
|
SPARX Group Establishes "Mirai Creation Fund IV" Toyota Motor Corporation, Sumitomo Mitsui Banking Corporation, MUFG Bank, Ltd. and Mizuho Bank, Ltd. to Provide Capital Targeting Total Commitments of JPY100 billion
May 12, 2026 19:29 JST
|
|
|
GTJAI Assists State Bank of Mongolia in Completing a US$100 Million Reg S Bond Tap Issuance
May 12, 2026 17:45 HKT/SGT
|
|
|
國泰君安國際協助蒙古國家銀行完成1億美元Reg S債券增發
May 12, 2026 17:45 HKT/SGT
|
|
|
国泰君安国际协助蒙古国家银行完成1亿美元Reg S债券增发
May 12, 2026 17:45 HKT/SGT
|
|
|
Casa Minerals Inc. Receives Proceeds of $432,777 from Warrant Exercises
May 12, 2026 17:29 HKT/SGT
|
|
|
Anytime Fitness加速亞太擴張
May 12, 2026 17:14 HKT/SGT
|
|
|
Anytime Fitness加速亚太扩张
May 12, 2026 17:14 HKT/SGT
|
|
|
CleverTap และ Rabbit Rewards คว้ารางวัล Silver จากเวที Thailand MarTech Awards 2026 ตอกย้ำความสำเร็จด้าน Real-time, Agentic Customer Engagement
May 12, 2026 15:00 HKT/SGT
|
|
|
CleverTap and Rabbit Rewards win Silver at Thailand MarTech Awards 2026 for real-time, agentic customer engagement
May 12, 2026 15:00 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
